Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments
- Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief Scientific Officer
- Janine Schuurman, PhD, Hans Clevers, MD, PhD, and David Sansom, PhD, join the Scientific Advisory Board
- Appointments strengthen Laigo’s leadership team following its €17m seed financing as the Company advances its SureTACs™ programs towards clinical development
UTRECHT, the Netherlands – 14 April 2026 – Laigo Bio (“Laigo”), a biotech company pioneering novel and highly differentiated therapies using its proprietary SureTACs™ precision membrane protein degradation platform, today announces the appointment of Dr. Richard C.A. Sainson as its new Chief Scientific Officer (CSO) and the establishment of its Scientific Advisory Board (SAB) comprising Dr. Janine Schuurman, Professor Dr. Hans Clevers and Professor David Sansom.
